UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2020

 

 

 

PROTAGONIST THERAPEUTICS, INC.

 

 

 

(Exact name of registrant as specified in its charter)

 

Delaware   001-37852   98-0505495
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

 

(510) 474-0170

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.00001   PTGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

At the Protagonist Therapeutics, Inc. (the “Company”) 2020 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 28, 2020, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 16, 2020. The results of the matters voted upon at the meeting were:

 

Proposal 1 — To elect the two Class I directors named below to serve until the 2023 Annual Meeting of Stockholders. Each of the two named nominees was so elected, with the votes thereon at the Annual Meeting as follows:

 

    Final Voting Results  
Nominees   For     Withheld     Broker Non-Votes  
Dinesh V. Patel, Ph.D.     16,515,423       1,916,749       3,542,396  
Sarah Noonberg, M.D., Ph.D.     16,397,931       2,034,241       3,542,396  

 

Proposal 2 — To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:

 

Final Voting Results  
For     Against     Abstain     Broker Non-Votes  
  21,966,944       3,185       4,439        

 

No other matters were submitted for stockholder action.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Protagonist Therapeutics, Inc.
Dated: May 29, 2020  
  By: /s/ Don Kalkofen
    Don Kalkofen
    Chief Financial Officer

 

 

 

Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Protagonist Therapeutics Charts.
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Protagonist Therapeutics Charts.